Loading
The updated American guideline for anaplastic thyroid cancer stresses molecular testing within days of diagnosis, BRAF-MEK inhibitors for BRAF-mutant disease including before surgery, multimodal therapy for resectable disease, and early goals-of-care discussions.
Evidence-based guideline covering rapid diagnosis and staging, airway management, molecular testing, surgery, radiotherapy with or without chemotherapy, BRAF-directed and other targeted therapy, immunotherapy, and palliative and supportive care for anaplastic thyroid cancer.
The anaplastic thyroid cancer page's emphasis on speed, BRAF testing and neoadjuvant targeted therapy follows this guideline.